Israeli biotech startup CytoReason has secured a total of $130 million in funding.

The recent $80 million investment came from investors such as OurCrowd, NVIDIA, Pfizer, and Thermo Fisher.

Nvidia's participation underscores its focus on AI technology investments, marking over 30 AI-related investments by the end of 2023.

CytoReason specializes in AI-driven disease modeling.

The funding will be used to expand CytoReason's models, data, and establish a US office in Cambridge, Massachusetts.

A strategic collaboration with Pfizer includes an initial $20 million investment, potentially reaching $110 million by 2027.

Partnerships with Pfizer and leading data organizations have helped CytoReason scale its AI-powered disease models.

CEO David Harel highlights the importance of data modeling in pharmaceutical R&D and aims to streamline drug development processes to benefit patients globally.